H Ihmsen1, G Geisslinger, J Schüttler. 1. Department of Anesthesiology, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany. harald.ihmsen@kfa.imed.uni-erlangen.de
Abstract
OBJECTIVE: We investigated the pharmacokinetics of ketamine with special regard to enantiomer-specific differences. METHODS:Ten healthy young male volunteers (mean age, 28 +/- 4 years; mean weight, 79 +/- 11 kg) received racemic ketamine and S(+)-ketamine in a randomized double-blind crossover study. Drugs were administered by a computer-controlled device. Two infusion cycles with linearly increasing targets [slope, 0.1 microg x ml(-1) x min(-1) for S(+)-ketamine and 0.2 microg x ml(-1) x min(-1) for racemic ketamine] were administered. Concentrations of the ketamine enantiomers were determined from arterial blood, and pharmacokinetic parameters were estimated with a 2- and 3-compartment model. RESULTS: The total doses needed to reach defined end points were 271 +/- 80 mg and 409 +/- 75 mg for S(+)-ketamine and racemic ketamine, respectively (P <.05). S(+)-ketamine showed a significantly higher clearance (26.3 +/- 3.5 ml x kg(-1) x min(-1)) compared with racemic ketamine (14.8 +/- 1.7 ml x kg(-1) x min(-1); P <.05) and R(-)-ketamine (13.8 +/- 1.3 ml x kg(-1) x min(-1); P <.05). Furthermore, the clearance of the S (+)-ketamine was smaller in the racemate (18.5 +/- 0.7 ml x kg(-1) x min(-1); P <.05) than for the pure isomer. CONCLUSIONS: These results demonstrate that R(-)-ketamine inhibits the elimination of S(+)-ketamine.
RCT Entities:
OBJECTIVE: We investigated the pharmacokinetics of ketamine with special regard to enantiomer-specific differences. METHODS: Ten healthy young male volunteers (mean age, 28 +/- 4 years; mean weight, 79 +/- 11 kg) received racemic ketamine and S(+)-ketamine in a randomized double-blind crossover study. Drugs were administered by a computer-controlled device. Two infusion cycles with linearly increasing targets [slope, 0.1 microg x ml(-1) x min(-1) for S(+)-ketamine and 0.2 microg x ml(-1) x min(-1) for racemic ketamine] were administered. Concentrations of the ketamine enantiomers were determined from arterial blood, and pharmacokinetic parameters were estimated with a 2- and 3-compartment model. RESULTS: The total doses needed to reach defined end points were 271 +/- 80 mg and 409 +/- 75 mg for S(+)-ketamine and racemic ketamine, respectively (P <.05). S(+)-ketamine showed a significantly higher clearance (26.3 +/- 3.5 ml x kg(-1) x min(-1)) compared with racemic ketamine (14.8 +/- 1.7 ml x kg(-1) x min(-1); P <.05) and R(-)-ketamine (13.8 +/- 1.3 ml x kg(-1) x min(-1); P <.05). Furthermore, the clearance of the S (+)-ketamine was smaller in the racemate (18.5 +/- 0.7 ml x kg(-1) x min(-1); P <.05) than for the pure isomer. CONCLUSIONS: These results demonstrate that R(-)-ketamine inhibits the elimination of S(+)-ketamine.
Authors: Michael E Goldberg; Marc C Torjman; Robert J Schwartzman; Donald E Mager; Irving W Wainer Journal: Pain Physician Date: 2010 Jul-Aug Impact factor: 4.965
Authors: Ruin Moaddel; Swarajya Lakshmi Vattem Venkata; Mary J Tanga; James E Bupp; Carol E Green; Lalitha Iyer; Anna Furimsky; Michael E Goldberg; Marc C Torjman; Irving W Wainer Journal: Talanta Date: 2010-08-13 Impact factor: 6.057
Authors: M Knobloch; C J Portier; O L Levionnois; R Theurillat; W Thormann; C Spadavecchia; M Mevissen Journal: Toxicol Appl Pharmacol Date: 2006-07-03 Impact factor: 4.219
Authors: Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould Journal: Pharmacol Rev Date: 2018-07 Impact factor: 25.468
Authors: Michael Sabia; Robert A Hirsh; Marc C Torjman; Irving W Wainer; Niti Cooper; Richard Domsky; Michael E Goldberg Journal: Curr Pain Headache Rep Date: 2011-06
Authors: Xiaochen Zhao; Swarajya Lakshmi Vattem Venkata; Ruin Moaddel; Dave A Luckenbaugh; Nancy E Brutsche; Lobna Ibrahim; Carlos A Zarate; Donald E Mager; Irving W Wainer Journal: Br J Clin Pharmacol Date: 2012-08 Impact factor: 4.335